Should we be screening for amblyopia?

Article

Amblyopia nearly doubles the lifetime risk of bilateral visual impairment.

Amblyopia nearly doubles the lifetime risk of bilateral visual impairment (BVI), according to a study published in the November issue of the British Journal of Ophthalmology.

Redmer van Leeuwen and colleagues from the Erasmus Medical Center, Rotterdam, The Netherlands conducted a study to determine whether the excess risk of BVI among subjects with amblyopia makes it worthwhile screening these subjects.

Risk was estimated by determining the incidence of BVI in the Rotterdam Study, a population-based cohort of subjects aged 55 years or over (n=5,220), including 192 individuals with amblyopia (3.7%). A multi-state life table was used to determine risk and excess periods spent with BVI.

It was found that, the relative risk of BVI for amblyopes was 2.6 (95% confidence interval 1.4-4.5). For subjects with amblyopia, the lifetime risk of BVI was 18% and they lived with this condition for an average of 7.2 years. For non-amblyopic individuals, these figures were 10% and 6.7 years, respectively.

Amblyopia nearly doubles the lifetime risk of BVI. The authors of this study therefore believe that the results can provide data for future cost-effectiveness analyses.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.